Clinical Features of Paraganglioma Syndromes

ABSTRACT

Head and neck paragangliomas (HNPs) and pheochromocytomas are rare tumors. Sporadic and hereditary forms are recognized. Four different paraganglioma syndromes (PGLs 1–4) have been described: PGL 1 is associated with mutations of the succinate dehydrogenase (SDH) subunit D (SDHD) gene; PGL 3 is caused by SDHC gene mutations; PGL 4 is caused by SDHB gene mutations; the susceptibility gene for PGL 2 is unknown. The objective of this study is to review distinct clinical features of the different PGLs. An international registry for HNPs was founded in Freiburg, Germany, in 2000. The data presented in this article have been acquired from registered HNP patients who have been screened for mutations of the genes SDHB, SDHC, and SDHD. Approximately 30% of apparent sporadic HNPs are caused by a germline mutation in one of these genes. Patients with PGL 1 or 4 have a very high lifetime risk of developing HNPs as well as thoracic and abdominal pheochromocytomas. Compared with sporadic HNPs, tumors developing in SDHB, SDHC, and SDHD mutation carriers arise at a significantly younger age. The SDHB mutations are associated with a high percentage of malignant paraganglionic tumors. We recommend molecular genetic screening of all HNP patients for SDHB, SDHC, and SDHD gene mutations. Mutation carriers must be screened for paraganglial tumors in the head, neck, thorax, and abdomen. Appropriately timed surgical intervention will minimize disease-specific morbidity and mortality. Lifelong follow-up is mandatory.

KEYWORDS

Paraganglioma - paraganglioma syndromes - pheochromocytoma - neuroendocrine tumors - succinate dehydrogenase subunits B - C - D

REFERENCES

• 1 Boedeker C C, Neumann H PH, Ridder G J, Maier W, Schipper J. Paragangliomas in patients with mutations of the SDHD gene.  Otolaryngol Head Neck Surg. 2005;  132 467-470
• 2 Neumann H P, Bausch B, McWhinney S R et al.. Germ-line mutations in nonsyndromic pheochromocytoma.  N Engl J Med. 2002;  346 1459-1466
• 3 Neumann H PH, Pawlu C, Peçzkowska M et al.. Distinct clinical features characterize paraganglioma syndromes associated with SDHB and SDHD gene mutations.  JAMA. 2004;  292 943-951
• 4 Schiavi F, Boedeker C C, Bausch B et al.. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene.  JAMA. 2005;  294 2057-2063
• 5 Sobol S M, Dailey J C. Familial multiple cervical paragangliomas: report of a kindred and review of the literature.  Otolaryngol Head Neck Surg. 1990;  102 382-390
• 6 Boedeker C C, Ridder G J, Schipper J. Paragangliomas of the head and neck: diagnosis and treatment.  Fam Cancer. 2005;  4 55-59
• 7 Chase W H. Familial and bilateral tumors of the carotid body.  J Pathol Bacteriol. 1933;  36 1-12
• 8 Gimm O, Armanios M, Dziema H, Neumann H PH, Eng C. Somatic and occult germline mutations in SDHD, a mitochondrial complex II gene, in non-familial pheochromocytomas.  Cancer Res. 2000;  60 6822-6825
• 9 Neumann H PH, Berger D P, Siegmund G et al.. Pheochromocytomas, multiple endocrine neoplasia type 2 and von Hippel-Lindau disease.  N Engl J Med. 1993;  329 1531-1538
• 10 Riccardi V M. Von Recklinghausen neurofibromatosis.  N Engl J Med. 1981;  305 1617-1627
• 11 Eng C, Clayton D, Schuffenecker I et al.. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.  JAMA. 1996;  276 1575-1579
• 12 Yip L, Lee J R, Shapiro S E et al.. Surgical management of hereditary pheochromocytoma.  J Am Coll Surg. 2004;  198 525-535
• 13 Baysal B E, Ferrell R E, Willett-Brozick J E et al.. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma.  Science. 2000;  287 848-851
• 14 Niemann S, Müller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3.  Nat Genet. 2000;  26 268-270
• 15 Astuti D, Latif F, Dallol A et al.. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma.  Am J Hum Genet. 2001;  69 49-54
• 16 Baysal B E, Willett-Brozick J E, Lawrence E C et al.. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas.  J Med Genet. 2002;  39 178-183
• 17 Astuti D, Douglas F, Lennard T W et al.. Germline SDHD mutation in familial phaeochromocytoma.  Lancet. 2001;  357 1181-1182
• 18 Niemann S, Müller U, Engelhardt D, Lohse P. Autosomal dominant malignant and catecholamine-producing paraganglioma caused by a splice donor site mutation in SDHC.  Hum Genet. 2003;  113 92-94
• 19 Bauters C, Vantyghem M C, Leteutre E et al.. Hereditary phaeochromocytomas and paragangliomas: a study of five susceptibility genes [letter].  J Med Genet. 2003;  40 E75
• 20 Baysal B E, Willett-Brozick J E, Andrade Filho P A et al.. An Alu-mediated partial SDHC deletion causes familial and sporadic paraganglioma.  J Med Genet. 2004;  41 703-709
• 21 Peczkowska M, Cascon A, Prejbisz A et al.. Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation.  Nat Clin Pract Endocrinol Metab. 2008;  4 111-115
• 22 Gimenez-Roqueplo A P, Favier J, Rustin P et al.. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.  Cancer Res. 2003;  63 5615-5621
• 23 Baysal B E. Hereditary paraganglioma targets diverse paraganglia.  J Med Genet. 2002;  39 617-622
• 24 Birch-Machin M A, Taylor R W, Cochran B, Ackrell B A, Turnbull D M. Late-onset optic atrophy, ataxia, and myopathy associated with a mutation of a complex II gene.  Ann Neurol. 2000;  48 330-335
• 25 Lee J H, Barich F, Karnell L H et al.. National Cancer Data Base report on malignant paragangliomas of the head and neck.  Cancer. 2002;  94 730-737
• 26 Persky M S, Setton A, Niimi Y, Hartman J, Frank D, Berenstein A. Combined endovascular and surgical treatment of head and neck paragangliomas: a team approach.  Head Neck. 2002;  24 423-431
• 27 Robbins K T, Clayman G, Levine P A American Head and Neck Society et al. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology–Head and Neck Surgery.  Arch Otolaryngol Head Neck Surg. 2002;  128 751-758
• 28 Vanharanta S, Buchta M, McWhinney S R et al.. Early onset renal cell carcinoma as novel extraparaganglial component of SDHB-associated hereditable paraganglioma.  Am J Hum Genet. 2004;  74 153-159
• 29 Hoegerle S, Ghanem N, Altehoefer C et al.. ¹⁸F-DOPA positron emission tomography for the detection of glomus tumours.  Eur J Nucl Med Mol Imaging. 2003;  30 689-694
• 30 Brink I, Hoegerle S, Klisch J, Bley T A. Imaging of pheochromocytoma and paraganglioma.  Fam Cancer. 2005;  4 61-68
• 31 Baysal B E. On the association of succinate dehydrogenase mutations with hereditary paraganglioma.  Trends Endocrinol Metab. 2003;  14 453-459
• 32 Hensen E F, Jordanova E S, van Minderhout I J et al.. Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families.  Oncogene. 2004;  23 4076-4083
• 33 Shapiro S E, Cote G C, Lee J E, Gagel R F, Evans D B. The role of genetics in the surgical management of familial endocrinopathy syndromes.  J Am Coll Surg. 2003;  197 818-831
• 34 Timmers H J, Pacak K, Bertherat J et al.. Mutations associated with succinate dehydrogenase D-related malignant paragangliomas.  Clin Endocrinol (Oxf). 2008;  68 561-566
• 35 Papaspyrou K, Rossmann H, Fottner C et al.. Malignant paraganglioma caused by a novel germline mutation of the succinate dehydrogenase D-gene: a case report.  Head Neck. 2008;  30 964-969
• 36 Boedeker C C, Neumann H PH, Bausch B, Maier W, Schipper J, Ridder G J. Malignant paragangliomas in SDHB mutation carriers.  Otolaryngol Head Neck Surg. 2007;  137 126-129